Aurinia To Present Six Abstracts, Including Five Poster Presentations, At The American Society Of Nephrology Kidney Week 2024 Taking Place In San Diego, October 23-27
Portfolio Pulse from Benzinga Newsdesk
Aurinia Pharmaceuticals will present six abstracts, including five poster presentations, at the American Society Of Nephrology Kidney Week 2024. The presentations will focus on LUPKYNIS® (voclosporin), a treatment for lupus nephritis, highlighting its clinical importance and real-world effectiveness.
October 11, 2024 | 10:14 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aurinia Pharmaceuticals is set to present data on LUPKYNIS® at ASN Kidney Week 2024, reinforcing its clinical importance for lupus nephritis treatment.
The presentation of six abstracts at a major nephrology conference highlights the importance of LUPKYNIS® in treating lupus nephritis. This could positively impact Aurinia's stock as it showcases the drug's effectiveness and potential market impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90